Deals & Corporate Governance
-
December 11, 2025
DOJ-UnitedHealth Deal Requiring Home Health Sale OK'd
A Maryland federal judge signed off on the U.S. Department of Justice settlement resolving its challenge to UnitedHealth's $3.3 billion acquisition of home health and hospice company Amedisys, under a deal requiring the sale of least 164 locations across 19 states.
-
December 11, 2025
Elevance Health Adds Former Pfizer GC To Its Board
Insurer Elevance Health has appointed former Pfizer Inc. general counsel Amy Schulman, currently a managing partner of Polaris Partners, to serve on its board of directors.
-
December 11, 2025
Sidley Guides Diagnostic Imaging Firm Lumexa's $463M IPO
Private equity-backed diagnostic imaging provider Lumexa Imaging Holdings Inc., led by Sidley Austin LLP, began trading Thursday on the Nasdaq Global Select Market after pricing a $463 million initial public offering.
-
December 11, 2025
4 Firms Guide As Arcline Exits Medical Tech Co. In $685M Deal
Perimeter Solutions Inc. has agreed to acquire Medical Manufacturing Technologies LLC from Arcline Investment Management for approximately $685 million in cash, including certain tax benefits.
-
December 10, 2025
Diagnostic Co. Agrees To Oversight Reforms In Derivative Suit
A California federal judge has granted preliminary approval to a deal ending shareholder derivative claims that diagnostics company CareDx's executives and directors damaged the company by concealing its scheme to inflate its testing services revenue.
-
December 10, 2025
Lincoln Property, PGIM Partner To Acquire Outpatient Centers
Global real estate firm Lincoln Property Co. and the real estate arm of PGIM Inc. have announced a strategic partnership aimed at pursuing investments in outpatient medical properties.
-
December 09, 2025
NJ Drugmaker, Chubb Settle $6.5M Defense Costs Suit
A New Jersey pharmaceutical company and Chubb have reached a settlement to end a lawsuit alleging the insurer owes nearly $6.5 million in outstanding legal fees stemming from a multibillion-dollar arbitration dispute over the development of a COVID-19 drug, according to a stipulation of dismissal from the companies.
-
December 09, 2025
PE-Backed Medical Supplies Giant Medline Eyes $5B IPO
Private equity-backed medical supplies behemoth Medline has outlined terms for its long-awaited initial public offering, telling U.S. regulators that it plans to raise about $5 billion in what would mark the largest IPO of 2025.
-
December 09, 2025
Tonix Pharmaceuticals Taps Lowenstein Sandler Atty As GC
Tonix Pharmaceuticals announced Tuesday that it added a former senior counsel at Lowenstein Sandler LLP as its new general counsel this week, months after the company announced the hiring of its previous general counsel in May.
-
December 08, 2025
Polsinelli Guides $113M Loan For Brooklyn Medical Facility
Capital One NA inked a $113.5 million loan for a medical property in Brooklyn in a deal guided by Polsinelli, part of a massive portfolio of outpatient medical buildings purchased by Remedy Medical Properties and Kayne Anderson Real Estate in the fall.
-
December 08, 2025
4 Firms Lead $1.51B TC Transcontinental Packaging Deal
Private equity-backed ProAmpac on Monday unveiled plans to acquire TC Transcontinental Packaging from TC Transcontinental in a $1.51 billion deal built by four law firms.
-
December 04, 2025
Prolonged FTC Review Kills $615M Healthcare Staffing Deal
Talent software and staffing company Aya Healthcare Inc. abandoned its planned $615 million deal for Cross Country Healthcare Inc. on Thursday, citing uncertainty from an ongoing Federal Trade Commission review that was extended by the government shutdown.
-
December 03, 2025
AT&T Sues Generic Drug Manufacturers, Alleging Price-Fixing
AT&T has joined the bevy of litigants suing a swath of pharmaceutical companies over alleged generic drug price-fixing, claiming it shelled out billions of dollars for medication reimbursements to the drugmakers as part of its employee health plans when it could have spent far less if the drugs weren't subject to anticompetitive pricing.
-
December 02, 2025
Fed. Circ. Erases $41.8M Verdict Over Seagen Cancer Drug IP
The Federal Circuit in a precedential opinion Tuesday reversed a $41.8 million verdict against Daiichi Sankyo for infringing a Seagen breast cancer treatment patent, saying a lower court should have found that the patent didn't adequately describe the claimed invention or enable a skilled person to use it.
-
November 26, 2025
Health Plans Defend Renewed Biogen MS Drug Scheme Suit
Health plans claiming Biogen Inc. illegally stifled competition for its multiple sclerosis drug Tecfidera have said an Illinois federal judge should let their latest complaint proceed to discovery because it fixes earlier pleading deficiencies and better outlines the drugmaker's allegedly anticompetitive scheme.
-
November 26, 2025
GTCR Drops FTC Constitutional Challenge Over Merger Case
GTCR BC Holdings LLC has agreed to dismiss its constitutional claims against the Federal Trade Commission after enforcers dropped their case challenging the private equity firm's $627 million purchase of medical device coatings company Surmodics Inc.
-
November 25, 2025
New Complaint Says Ex-Execs Turned Steward Into 'Zombie'
Bankrupt hospital operator Steward Health has filed hundreds of millions in new claims in Texas bankruptcy court against its former CEO and other executives, including allegations that they orchestrated a sale-leaseback deal that rendered the business an insolvent "zombie."
-
November 24, 2025
FTC Abandons In-House GTCR Merger Case After Court Loss
The Federal Trade Commission formally dropped its administrative case challenging GTCR BC Holdings LLC's acquisition of a medical coatings supplier after an Illinois federal judge refused to put the deal on hold.
-
November 24, 2025
Justices Refuse Drug Price-Fixing Class Action
The U.S. Supreme Court said Monday that it will not review the Fourth Circuit's decision to back the dismissal of a proposed class action accusing drugmakers of conspiring and inflating the price of a medication for Huntington's disease.
-
November 20, 2025
FTC Withdraws In-House GTCR Merger Case
The Federal Trade Commission withdrew its administrative case challenging GTCR BC Holdings LLC's acquisition of a medical coatings supplier to consider whether to drop the case entirely after an Illinois federal judge refused to put the merger on hold.
-
November 19, 2025
Is 'Red Book' Best For Drug Pricing? Pa. Justices Ask
The Pennsylvania Supreme Court seemed skeptical Wednesday that the state workers' compensation authorities were using the best guide to calculate pharmacy reimbursements for injured workers' prescription drugs, with the justices questioning the fairness of the industry's long-used "red book" method.
-
November 19, 2025
GTCR Wants FTC's In-House Merge Case Withdrawn Too
GTCR BC Holdings LLC wants the Federal Trade Commission to rethink its in-house challenge to a medical coatings supplier merger after an Illinois federal judge refused a temporary block and the FTC opted not to appeal that rejection.
-
November 18, 2025
Healthcare Deals This Week: Merck, Sofinnova, Lilly
Merck and Eli Lilly announced billion-dollar transactions set to give them an in on new treatments. Pfizer was victorious after beating out GLP-1 maker Novo Nordisk in a battle for Metsera. Law360 looks at the big deals from the past week.
-
November 18, 2025
Perrigo Sued Over Misstatements On Infant Formula Business
Perrigo Company PLC faces a shareholder class action alleging the company and its top brass failed to disclose critical issues with infant formula operations that it purchased from Nestle and caused stock prices to drop as the issues came to light.
-
November 18, 2025
McGuireWoods Is Delaying Defamation Case, NC Justices Told
The former CEO of a managed care organization who alleges McGuireWoods and one of its ex-partners defamed him during a press conference more than seven years ago has told North Carolina's top court not to take up the case, panning their petition as yet another stalling tactic.
Expert Analysis
-
Texas Med Spas Must Prepare For 2 New State Laws
Two new laws in Texas — regulating elective intravenous therapy and reforming healthcare noncompetes — mark a pivotal shift in the regulatory framework for medical spas in the state, which must proactively adapt their operations and contractual practices, says Brad Cook at Munsch Hardt.
-
Strategies For Cos. Navigating US-Indian Pharma Partnerships
Recent policy adjustments implemented by the U.S. government present both new opportunities and heightened regulatory scrutiny for the Indian life sciences industry, amplifying the importance of collaboration between the Indian and U.S. pharmaceutical sectors, say Bryant Godfrey at Foley Hoag and Jashaswi Ghosh at Holon Law Partners.
-
A Look At Key 5th Circ. White Collar Rulings So Far This Year
In the first half of 2025, the Fifth Circuit has decided numerous cases of particular import to white collar practitioners, which collectively underscore the critical importance of meticulous recordbuilding, procedural compliance and strategic litigation choices at every stage of a case, says Joe Magliolo at Jackson Walker.
-
A Look At Trump 2.0 Antitrust Enforcement So Far
The first six months of President Donald Trump's second administration were marked by aggressive antitrust enforcement tempered by traditional structural remedies for mergers, but other unprecedented actions, like the firing of Federal Trade Commission Democrats, will likely stoke heated discussion ahead, says Richard Dagen at Axinn.
-
Plan For Increased HSR Info Sharing With Wash. Antitrust Law
Washington's merger notification requirements, effective later this month, combined with the Federal Trade Commission's new Hart-Scott-Rodino Act rules, will result in greater information sharing among state and federal agencies, making it important for merging parties to consider their transaction's potential state antitrust implications early on, say attorneys at McDermott.
-
Spinoff Transaction Considerations For Biotech M&A
Amid current market challenges, boards and management teams of biotech companies can consider several strategies for maximizing value should a spinoff opportunity arise, but not without significant advance planning and careful implementation, particularly in cases that might qualify as tax-free, say attorneys at Paul Hastings.
-
How Ore. Law Puts New Confines On Corp. Health Ownership
A newly enacted law in Oregon strengthens the state’s restrictions on corporate ownership of healthcare practices, with new limitations on overlapping control, permissible services, restrictive covenants and more making it necessary for practices to review decades-old physician practice arrangements, say attorneys at Ropes & Gray.
-
Trump Antitrust Shift Eases Pressure On Private Equity Deals
Enforcement actions and statements by Trump administration antitrust officials forecast a shift away from specifically targeting private equity activity, which should be welcome news to dealmakers, but firms shouldn't expect to escape traditional antitrust scrutiny, says Nathaniel Bronstein at Fried Frank.
-
How Trump Administration's Antitrust Agenda Is Playing Out
Under the current antitrust agency leadership, the latest course in merger enforcement, regulatory approach and key sectors shows a marked shift from Biden-era practices and includes a return to remedies and the commitment to remain focused on the bounds of U.S. law, say attorneys at Wilson Sonsini.
-
Why Texas Should Slow Down On Healthcare Merger Bills
More time is needed to study three Texas bills aimed at considering the effects of healthcare consolidation to increase affordability and access to healthcare, which could have the opposite effect, say John Saran and Harshita Rathore at Holland & Knight and Robbie Allen at U.S. Heart and Vascular.
-
Navigating The Expanding Frontier Of Premerger Notice Laws
Washington's newly enacted law requiring premerger notification to state enforcers builds upon a growing trend of state scrutiny into transactions in the healthcare sector and beyond, and may inspire other states to enact similar legislation, say attorneys at Simpson Thacher.
-
Issues To Watch At ABA's Antitrust Spring Meeting
Attorneys at Freshfields consider the future of antitrust law and competition enforcement amid agency leadership changes and other emerging developments likely to dominate discussion at the American Bar Association's Antitrust Spring Meeting this week.
-
Reviewing Calif. Push To Restrict Private Equity In Healthcare
A recent proposed bill in California aims to broaden the state's existing corporate practice of medicine restrictions, so investors must ensure that there is clear delineation between private equity investment in practice management and physicians' clinical decision-making, say attorneys at Debevoise.